Raymond James analyst David Novak reiterated a Strong Buy rating on Zymeworks (NYSE: ZYME) after the company announced a new ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE